Pear Therapeutics touts Q2 growth while scaling back full-year goals and chopping 9% of staff

Nicole DeFeudis

Editor

Pear Therapeutics set some ambitious goals back in March, predicting a five-fold boost in revenue and a surge in new prescriptions for its digital therapeutics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Pear Therapeutics touts Q2 growth while scaling back full-year goals and chopping 9% of staff

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

BioMarin turns to ex-Roche dealmaker James Sabry to build ‘next version’ of 27-year-old company

Purdue, Sacklers reach new $7.4B opioid settlement after SCOTUS rejection

As another Trump term gets underway, pharma advisors get comfortable with uncertainty

AbbVie partners with Neomorph in latest molecular glue deal

Updated: Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’

Fueling More Breakthroughs: Manufacturing Innovation to Expand Gene Therapy’s Reach

Pear Ther­a­peu­tics touts Q2 growth while scal­ing back full-year goals and chop­ping 9% of staff

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Pear Therapeutics touts Q2 growth while scaling back full-year goals and chopping 9% of staff